|
EP1938812A1
|
|
Pharmaceutical composition using aliskiren and avosentan
|
|
BRPI0615794A2
|
|
pyridylsulfonamidylpyrimidines for the prevention of blood vessel graft failure
|
|
EP1842543A1
|
|
Pharmaceutical composition coprising an aldosterone synthase inhibitor and a mineralcorticoid receptor antagonist
|
|
EP1595880A1
|
|
Crystalline forms of a pyridinyl-sulfonamide and their use as endothelin receptor antagonists
|
|
RS20050683A
|
|
New medicament
|
|
WO2004002466A1
|
|
Pharmaceutical formulation comprising non-peptide renin inhibitor and surfactant
|
|
CA2445014A1
|
|
Process for the preparation of substituted carboxylic acid esters by enzymatic hydrolysis
|
|
EP1215201A2
|
|
Process for the preparation of aryloctanoyl amides
|
|
CN1817872A
|
|
Process for the preparation of substituted octanoyl amides
|
|
CN1440381A
|
|
Process for preparation of substituted octanoyl amides
|
|
AU7376201A
|
|
Process for the preparation of (r)-2-alkyl-3-phenyl-1-propanols
|
|
WO0202500A1
|
|
Preparation of (r)-2-alkyl-3-phenylpropionic acids
|
|
WO0208172A1
|
|
Process for the preparation of substituted octanoyl amides
|
|
TW550248B
|
|
Preparation of N-substituted 2,7-dialkyl-4-hydroxy-5-amino-8-aryl-octanoyl amides
|
|
TWI271399B
|
|
2-alkyl-5-halogen-pent-4-enecarboxylic acids and their preparation
|
|
EP1200384A1
|
|
2-alkyl-5-halogen-pent-4-ene carboxylic acids and their production
|
